IL143905A0 - Novel streptococcus antigens - Google Patents

Novel streptococcus antigens

Info

Publication number
IL143905A0
IL143905A0 IL14390599A IL14390599A IL143905A0 IL 143905 A0 IL143905 A0 IL 143905A0 IL 14390599 A IL14390599 A IL 14390599A IL 14390599 A IL14390599 A IL 14390599A IL 143905 A0 IL143905 A0 IL 143905A0
Authority
IL
Israel
Prior art keywords
streptococcus antigens
novel streptococcus
novel
antigens
streptococcus
Prior art date
Application number
IL14390599A
Other languages
English (en)
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22351610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL143905(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Publication of IL143905A0 publication Critical patent/IL143905A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
IL14390599A 1998-12-23 1999-12-20 Novel streptococcus antigens IL143905A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11380098P 1998-12-23 1998-12-23
PCT/CA1999/001218 WO2000039299A2 (en) 1998-12-23 1999-12-20 Streptococcus antigens

Publications (1)

Publication Number Publication Date
IL143905A0 true IL143905A0 (en) 2002-04-21

Family

ID=22351610

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14390599A IL143905A0 (en) 1998-12-23 1999-12-20 Novel streptococcus antigens
IL143905A IL143905A (en) 1998-12-23 2001-06-21 Streptococcus antigens
IL194230A IL194230A (en) 1998-12-23 2008-09-21 Streptococcus antigens and processes for their production

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL143905A IL143905A (en) 1998-12-23 2001-06-21 Streptococcus antigens
IL194230A IL194230A (en) 1998-12-23 2008-09-21 Streptococcus antigens and processes for their production

Country Status (30)

Country Link
EP (2) EP2261358B1 (de)
JP (2) JP4761623B2 (de)
KR (4) KR100802198B1 (de)
CN (3) CN101134775A (de)
AP (1) AP2001002199A0 (de)
AR (1) AR029322A1 (de)
AT (1) ATE394489T1 (de)
AU (1) AU1764900A (de)
BR (1) BR9916477A (de)
CA (1) CA2356836C (de)
CL (1) CL2009002037A1 (de)
CY (3) CY1108223T1 (de)
CZ (2) CZ302790B6 (de)
DE (1) DE69938670D1 (de)
DK (3) DK1141306T3 (de)
EA (1) EA007409B1 (de)
ES (3) ES2306528T3 (de)
HK (1) HK1118575A1 (de)
HU (1) HU229664B1 (de)
IL (3) IL143905A0 (de)
MX (1) MXPA01006427A (de)
NO (1) NO330800B1 (de)
NZ (1) NZ512574A (de)
OA (1) OA11736A (de)
PL (3) PL205041B1 (de)
PT (3) PT2261358E (de)
TR (2) TR200102497T2 (de)
UY (1) UY25877A1 (de)
WO (1) WO2000039299A2 (de)
ZA (1) ZA200105114B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2280072B1 (de) 1998-02-20 2015-03-25 ID Biomedical Corporation of Quebec Gruppe B-Streptococcus Antigene
EP1801218A3 (de) * 1998-07-27 2007-10-10 Sanofi Pasteur Limited Nukleinsäuren und Proteine aus Pneumokokken
US20030134407A1 (en) 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
US6582706B1 (en) 1998-12-21 2003-06-24 Medimmune, Inc. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
PT2261358E (pt) * 1998-12-23 2014-07-30 Id Biomedical Corp Quebec Antigénios de streptococcus
US6866855B2 (en) 2000-06-12 2005-03-15 University Of Saskatchewan Immunization of dairy cattle with GapC protein against Streptococcus infection
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
CA2411919C (en) 2000-06-12 2012-07-31 University Of Saskatchewan Immunization of dairy cattle with chimeric gapc protein against streptococcus infection
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
NZ553554A (en) 2000-06-20 2008-11-28 Id Biomedical Corp Streptococcus antigens
WO2002079475A2 (en) * 2001-03-30 2002-10-10 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
DE60234772D1 (de) * 2001-07-06 2010-01-28 Id Biomedical Corp Gruppe-b streptococcus antigene und entsprechende dna-fragmente
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
DK1601770T3 (da) 2003-03-04 2009-11-02 Intercell Ag Streptococcus pyogenes antigener
EP2298934A1 (de) 2003-04-15 2011-03-23 Intercell AG S. pneumoniae Antigene
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AR058592A1 (es) 2005-12-22 2008-02-13 Glaxosmithkline Biolog Sa Vacuna
JP2010531330A (ja) 2007-06-26 2010-09-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
WO2009012588A1 (en) * 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
PL2271360T3 (pl) 2008-04-16 2016-03-31 Glaxosmithkline Biologicals Sa Szczepionka
WO2010036945A2 (en) 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
CA2757620C (en) 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
ES2670576T3 (es) 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
CN103501808A (zh) 2010-12-03 2014-01-08 赛诺菲巴斯德有限公司 用于针对肺炎链球菌免疫的组合物
KR20140017554A (ko) 2011-01-20 2014-02-11 제노시아 바이오사이언스, 인크. 폐렴 구균에 대한 백신 및 조성물
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
AU2012257771C1 (en) 2011-05-17 2015-12-03 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
KR102055463B1 (ko) * 2012-01-05 2019-12-12 도이체스 크렙스포르슝스첸트룸 Idh1 r132h 돌연변이체-양성 암의 치료 또는 진단을 위한 수단 및 방법
EP2931743A4 (de) * 2012-12-14 2016-08-03 Sanofi Pasteur Ltd Verfahren zur beurteilung der immunogenität
AU2015208820B2 (en) 2014-01-21 2020-05-14 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
EP4286000A3 (de) 2014-01-21 2024-02-14 Pfizer Inc. Kapsulare polysaccharide aus streptococcus pneumoniae und konjugate davon
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3206112A1 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10668164B2 (en) 2014-02-14 2020-06-02 Pfizer Inc. Immunogenic glycoprotein conjugates
HRP20230416T1 (hr) 2015-01-15 2023-07-07 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
MX2019008564A (es) 2017-01-20 2019-09-19 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas.
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
MX2022001241A (es) 2019-07-31 2022-04-20 Sanofi Pasteur Inc Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
EP4051696A1 (de) 2019-11-01 2022-09-07 Pfizer Inc. Escherichia-zusammensetzungen und verfahren dafür
IL295713A (en) 2020-02-21 2022-10-01 Pfizer Isolation of saccharides
AU2021223184A1 (en) 2020-02-23 2022-08-18 Pfizer Inc. Escherichia coli compositions and methods thereof
US20230383324A1 (en) 2020-10-22 2023-11-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4333879A1 (de) 2021-05-03 2024-03-13 Pfizer Inc. Impfung gegen bakterielle und betacoronavirus-infektionen
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20240090A1 (es) 2021-05-28 2024-01-16 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
HU217582B (hu) * 1993-03-19 2000-02-28 Gunnar Lindahl Streptococcus B csoportba tartozó törzsek elleni immunitást biztosító, Rib fehérjenevű felületi protein, eljárás a protein tisztítására, reagenskészlet és gyógyszerkészítmény
HUP0600442A3 (en) * 1995-06-07 2007-03-28 Biochem Vaccines Inc Streptococcal heat shock proteins members of the hsp70 family
US5928895A (en) * 1996-09-24 1999-07-27 Smithkline Beecham Corporation IgA Fc binding protein
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
ES2277362T5 (es) * 1996-10-31 2014-12-18 Human Genome Sciences, Inc. Antígenos y vacunas de streptococcus pneumoniae
BR9812525A (pt) * 1997-09-24 2000-07-25 Univ Minnesota Proteinase degradadora de complemento humano c3 de streptococcus pneumoniae
JP2002516251A (ja) * 1998-04-23 2002-06-04 ユーエイビー リサーチ ファンデーション 肺炎球菌表面プロテインＣ（ＰｓｐＣ）のエピトープ領域およびその菌株選択、ならびにそのための使用法
DE69935986D1 (de) * 1998-07-27 2007-06-14 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
WO2000006738A2 (en) * 1998-07-27 2000-02-10 Microbial Technics Limited NUCLEIC ACIDS AND PROTEINS FROM $i(STREPTOCOCCUS PNEUMONIAE)
CA2343931A1 (en) * 1998-09-24 2000-03-30 Regents Of The University Of Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
US6582706B1 (en) * 1998-12-21 2003-06-24 Medimmune, Inc. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
PT2261358E (pt) * 1998-12-23 2014-07-30 Id Biomedical Corp Quebec Antigénios de streptococcus

Also Published As

Publication number Publication date
PL349777A1 (en) 2002-09-09
HK1118575A1 (en) 2009-02-13
DK1950302T3 (da) 2013-01-14
CZ20012161A3 (cs) 2001-10-17
AP2001002199A0 (en) 2001-09-30
IL143905A (en) 2011-05-31
WO2000039299A3 (en) 2000-11-02
BR9916477A (pt) 2004-06-22
CN1654657A (zh) 2005-08-17
JP5039802B2 (ja) 2012-10-03
PL206576B1 (pl) 2010-08-31
KR20060134227A (ko) 2006-12-27
CY1108223T1 (el) 2014-02-12
IL194230A (en) 2013-12-31
NO330800B1 (no) 2011-07-18
ES2400280T3 (es) 2013-04-08
PL204073B1 (pl) 2009-12-31
PL205041B1 (pl) 2010-03-31
EP2261358B1 (de) 2014-05-14
KR101078919B1 (ko) 2011-11-01
JP2002533123A (ja) 2002-10-08
ES2480417T3 (es) 2014-07-28
HU229664B1 (en) 2014-04-28
EA007409B1 (ru) 2006-10-27
PT1950302E (pt) 2013-01-16
NO20013045D0 (no) 2001-06-19
IL194230A0 (en) 2011-08-01
CA2356836C (en) 2011-09-13
KR20010104693A (ko) 2001-11-26
CN101134775A (zh) 2008-03-05
DE69938670D1 (de) 2008-06-19
ES2306528T3 (es) 2008-11-01
DK1141306T3 (da) 2008-08-18
TR200200633T2 (tr) 2002-06-21
CN1191362C (zh) 2005-03-02
EP1141306B1 (de) 2008-05-07
KR100891398B1 (ko) 2009-04-02
PT2261358E (pt) 2014-07-30
EA200100565A1 (ru) 2002-04-25
KR101170203B1 (ko) 2012-07-31
MXPA01006427A (es) 2002-06-04
CZ303675B6 (cs) 2013-02-27
ZA200105114B (en) 2002-11-21
DK2261358T3 (da) 2014-07-28
JP2010142246A (ja) 2010-07-01
CZ302790B6 (cs) 2011-11-09
EP1141306A2 (de) 2001-10-10
EP2261358A3 (de) 2011-02-23
PT1141306E (pt) 2008-07-30
AR029322A1 (es) 2003-06-25
CY1114722T1 (el) 2016-10-05
HUP0104774A2 (hu) 2002-04-29
CN100398653C (zh) 2008-07-02
EP2261358A2 (de) 2010-12-15
CA2356836A1 (en) 2000-07-06
CY1115340T1 (el) 2017-01-04
NO20013045L (no) 2001-08-20
UY25877A1 (es) 2000-08-21
KR100802198B1 (ko) 2008-02-11
CN1332803A (zh) 2002-01-23
ATE394489T1 (de) 2008-05-15
HUP0104774A3 (en) 2007-10-29
TR200102497T2 (tr) 2002-01-21
KR20100063814A (ko) 2010-06-11
WO2000039299A2 (en) 2000-07-06
AU1764900A (en) 2000-07-31
CL2009002037A1 (es) 2010-06-25
JP4761623B2 (ja) 2011-08-31
KR20080036666A (ko) 2008-04-28
OA11736A (en) 2005-06-12
NZ512574A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
IL194230A0 (en) Novel streptococcus antigens
AU7038101A (en) Streptococcus antigens
ZA991325B (en) Novel group B streptococcus antigens.
GB9809839D0 (en) Antibody
AU2002351623A8 (en) Streptococcus antigens
GB9603256D0 (en) Antibodies
PL341642A1 (en) Novel macrolydes
PL341160A1 (en) Novel superficial antigen
PL346369A1 (en) Streptococcus suis
EP1068213A4 (de) Siloxane mit amino-organischer funktioneller gruppe
DE60023158D1 (en) Phagenresistentes streptococcus thermophilus
GB9818915D0 (en) Antibodies
GB9828700D0 (en) Antibody
IL138958A0 (en) Streptococcus preparation
GB9928678D0 (en) Streptococcus pneumoniae antigens
GB9825184D0 (en) Antigen
GB9807062D0 (en) Immune response
GB9915419D0 (en) Antigens
PL345071A1 (en) Novel biocontrol agents
GB9800760D0 (en) Antigens
GB9726147D0 (en) Antigens
GB9819411D0 (en) Antibodies
GB9819015D0 (en) Antigens
GB9822143D0 (en) Antigens
TW407677U (en) Form